NCT06153979View on ClinicalTrials.gov

Investigation of Immune Amnesia Following Measles Infection in Select African Regions

Active, not recruitingOBSERVATIONAL
Enrollment

256

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Measles Infection
Interventions
BIOLOGICAL

Verorab

Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.

Trial Locations (2)

Unknown

Partnership of Clinical Research in Guinea, Partenariat Pour La Recherche Clinique en Guinée (PREGUI), Conakry

University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako, Bamako

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT06153979 - Investigation of Immune Amnesia Following Measles Infection in Select African Regions | Biotech Hunter | Biotech Hunter